Skip to Main Content

Paper Details

COVID-19 and metabolic disease: mechanisms and clinical management.
Lancet Diabetes Endocrinol
119
2021
COVID-19, SARS, SARS-CoV-2, diabetes, hypertension, metabolic and endocrine disorders, metabolic and vascular disorders, metabolic disease, metabolic disorders, metabolic dysfunction, non-alcoholic fatty liver disease, obesity, patients, people
Author NameAffiliation
Peter E H SchwarzUniversity Hospital Carl Gustav Carus, Technische Universitat Dresden, Germany Paul Langerhans Institute Dresden, Germany German Center for Diabetes Research
Paul ZimmetCentral Clinical School, Monash University
Martin Hrab?? de AngelisGerman Center for Diabetes Research, Germany Institute of Experimental Genetics, Technische Universitat Munchen
Martin Hrab?? de AngelisGerman Center for Diabetes Research, Germany Institute of Experimental Genetics, Technische Universitat Munchen
Bernhard O BoehmTan Tock Seng Hospital, Singapore Lee Kong Chian School of Medicine, Nanyang Technological University
Juliana C N ChanHong Kong Institute of Diabetes and Obesity, China Li Ka Shing Institute of Health Science, Chinese University of Hong Kong and Prince of Wales Hospital
Abdul BasitBaqai Institute of Diabetology and Endocrinology, Baqai Medical University
Stefan R BornsteinUniversity Hospital Carl Gustav Carus, Technische Universitat Dresden, Germany Paul Langerhans Institute Dresden, Germany German Center for Diabetes Research, Diabetology and Clinical Nutrition, University Hospital Zurich, Kings College London
  • 1 - 8

Datasets